Hepatocellular Carcinoma
Conditions
Brief summary
Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and CTLA-4, which has the potential to boost immune surveillance in tumors. The goal of this clinical trial is to evaluated the efficacy and safety of cadonilimab combined with TACE in patients with intermediate-stage unresectable hepatocellular carcinoma.
Interventions
DRUGCadonilimab+TACE
Cadonilimab: 15mg/kg Q3W Day1 Select the best TACE treatment strategy. Traditional TACE (cTACE) or DEB-TACE can be selected. TACE treatment can be continued as needed based on disease control. The combination of cadonilimab is given 3 to 7 days after the first TACE treatment, and the subsequent administration of cardonilizumab is given once every 3 weeks, if the time overlaps with TACE treatment, it is generally administered 3 to 7 days after TACE treatment. Treatment was discontinued until intolerable toxicity, death, withdrawal of informed consent, initiation of a new antitumor therapy, or other reason specified in the protocol, whichever occurs first. Patients in this study received cadonilimab for up to 24 months.
Sponsors
Eastern Hepatobiliary Surgery Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. written informed consent signed prior to enrolment. 2. age \> 18 years, both sexes 3. patients with histologically or pathologically confirmed intermediate hepatocellular carcinoma; BCLC stage B or CNLC stage II 4. no previous antitumor therapy 5. Child-Pugh A or B7. 6. with measurable lesions (≥10 mm long diameter on CT scan for non-lymph node lesions and ≥15 mm short diameter on CT scan for lymph node lesions according to RECIST 1.1 criteria). 7. ECOG PS score: 0 to 1. 8. expected survival of \>12 weeks. 9. Adequate organ function
Exclusion criteria
1. BCLC C stage HCC 2. In combined with severe heart, lung, kidney or other important organ dysfunction, or combined with serious infection or other serious associated diseases, that cannot tolerate treatment (\> CTCAE Version 5.0 adverse events of grade 2). 3. With uncontrolled hepatitis B (HBV-DNA\>2000 IU/ml and elevated ALT). 4. Multi-nodules hepatocellular carcinoma beyond hemi-hepatic range. 5. Patients with tumor thrombus reaches or exceeds the portal vein. 6. History of other malignancies. 7. History of allergic reactions to related drugs. 8. History of organ transplantation. 9. Pregnant women, nursing mothers. 10. Patients have other factors that may interfere with patient enrollment and assessment results. 11. Refuse follow-up as required by this study protocol and refuse to sign informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | Up to 1 year | ORR is defined as the percentage of participants who have a confirmed complete response or partial response according to RECIST 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | Up to two years | PFS is defined as the time from enrollment of the trial to the first documented disease progression or death due to any cause. |
| Overall survival (OS) | Up to two years | The duration from the date of recruitment to the date of death from any cause. |
| Adverse events (safety) | Up to two years | Adverse events (safety ) will be evaluated according to the NCI CTCAE Version 5.0.The number and severity of treatment-related side effects, including AE and SAE, will be recorded during treatment. |
Countries
China
Outcome results
None listed